CDC/ACIP [to 18 February 2017]

CDC/ACIP [to 18 February 2017]
http://www.cdc.gov/media/index.html
http://www.cdc.gov/vaccines/acip/

MMWR Weekly February 17, 2017 / No. 6
[Excerpts]
:: Update: Influenza Activity — United States, October 2, 2016–February 4, 2017
:: Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017
…This report uses data, as of February 4, 2017, from 3,144 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during November 28, 2016–February 4, 2017, to estimate an interim adjusted effectiveness of seasonal influenza vaccine for preventing laboratory-confirmed influenza virus infection associated with medically attended ARI. During this period, overall vaccine effectiveness (VE) (adjusted for study site, age group, sex, race/ethnicity, self-rated general health, and days from illness onset to enrollment) against influenza A and influenza B virus infection associated with medically attended ARI was 48% (95% confidence interval [CI] = 37%–57%). Most influenza infections were caused by A (H3N2) viruses. VE was estimated to be 43% (CI = 29%–54%) against illness caused by influenza A (H3N2) virus and 73% (CI = 54%–84%) against influenza B virus….
:: Transmission of Zika Virus — Haiti, October 12, 2015–September 10, 2016
:: Notes from the Field: Ongoing Cholera Epidemic — Tanzania, 2015–2016

Register for upcoming February ACIP meeting
February 22-23, 2017
Deadline for registration:
:: Non-US Citizens: February 1, 2017; US Citizens: February 13, 2017
Registration is NOT required to watch the live meeting webcast or to listen via telephone.